Introduction
Diffuse large B-cell lymphomas (DLBCL), as defined by the Revised European-American Lymphoma (REAL) classification 1 and by the World Health Organization (WHO) classification of lymphoid neoplasms, 2, 3 are a heterogeneous group of aggressive lymphomas with an overall cure rate of approximately 50% in advanced and 70% in localized stages. [4] [5] [6] The poor histopathological reproducibility of the major DLBCL subtypes recognized by the Kiel classification, 7 that is, centroblastic (CB) and immunoblastic (IB) lymphoma, and a similar treatment for all subtypes has prompted the International Lymphoma Study Group in 1994 to create the 'entity' DLBCL. 1 Although DLBCLs were supposed to have a uniform clinical outcome, two studies have established IB histology according to the updated Kiel classification as a significant risk factor (RF) independent of other prognostic features 8 (Lopez-Guillermo et al. (Ann Oncol 1999; 88(Suppl. 3): 10, abstr.). Moreover, a cytogenetic study has provided some evidence supporting biological differences between CB and IB lymphomas. 9 In recent years, molecular profiling has been used for the improvement of diagnostics and prediction of survival. 10, 11 In these studies, basically three independent genetic signatures have been identified, that is, lymphomas with germinal center-cell-like, activated B-cell-like and a so-called type-3 gene-expression profile. It was shown that patients with a germinal center B-like DLBCL had a significantly better overall survival (OS) than those of the other groups. Immunophenotypic assignment of DLBCL into four groups according to differentiation was yet not able to predict survival in a recent study. 12 Still, the molecular predictors have not been incorporated into standard diagnostic procedures. Therefore, expert hematopathologists and oncologists still agree to retain the encompassing term DLBCL, as there are no reliable biological and clinical criteria for subclassification, 2, 3 but it is worth noting that most cases of DLBCL will conform to one of six morphological variants listed in the WHO classification; it was also proposed to develop criteria for these categories and to test them in clinical studies. 2 Among the six morphological variants of DLBCL, a plasmablastic variant has been acknowledged in the WHO classification, 3 which was described in HIV-positive patients with lymphomas of the oral cavity. 13 However, it has been noted that a number of DLBCL (particularly IB lymphomas) arising in HIV-negative patients also may have features of plasmacytoid or plasmablastic differentiation. 7, 10, 11 Accordingly, the association of HHV-8 with a plasmablastic variant of Castleman's disease (CD) in the context with overt plasmablastic lymphoma has been reported only recently.
14 Most plasmablastic lymphomas thus arise in the setting of viral infection and/or immunodeficiency. Another rare morphologic variant of DLBCL has been termed 'DLBCL with the expression of full-length ALK', and these lymphomas share a clearcut plasmablastic morphology. Recently, it has been demonstrated that most of these cases do not express full-length ALK, but instead show a translocation of ALK to the clathrin (CLTC) gene on chromosome 17. 15, 16 Even the 'classical' translocation t(2;5)(p23;q35) involving the nucleophosmin (NPM) gene on chromosome 5q has been reported in two plasmablastic lymphomas. 17 Thus, the term 'plasmablastic' seems to encompass a wide and ever-growing spectrum of lymphomas with different clinical and biological features.
Over the last decade, we have observed sporadic cases of DLBCL with plasmablastic/plasmacytoid features (PB/PC-Fs) in immunocompetent patients. It was the strikingly poor clinical outcome of these patients observed over the years that prompted us to evaluate the clinical significance of these lymphomas compared with two variants of DLBCL morphologically closely related and already listed in the WHO classification, namely CB and IB lymphomas. We retrospectively analyzed patients with DLBCL seen in our Department from January 1991 to May 2000. The samples were classified by defined histological criteria at two independent pathology units (Vienna, Austria and Wü rzburg, Germany). The outcome of patients unequivocally diagnosed with PB/PC-F was then compared with that of CB and IB lymphoma patients.
Material and methods

Patients
Between January 1991 and May 2000, a total of 147 patients with primary DLBCL were treated at the Department of Internal Medicine, Division of Hematology, University of Vienna.
Of these, 66 patients with DLBCL were enrolled in this study. The discrepancy of patients treated and patients in fact enrolled in this study is explained on the one hand due to the lack of histological material of lymphoma samples, on the other due to the selection criteria: patients with unclassified DLBCL (n ¼ 20), as well as DLBCL of other morphologic variants (eg anaplastic (n ¼ 2)-or T-cell-rich B-cell lymphomas (n ¼ 8) and distinct subtypes of DLBCL, for example, mediastinal large B-cell lymphoma (n ¼ 8) or intravascular lymphoma (n ¼ 1)) were not enrolled.
Patients had no evidence of HIV infection and no evidence of a preceding low-grade lymphoma or any other history of lymphomatous disease. Two patients started treatment in another hospital and were referred to our department during the course of their disease. All patients were staged with complete physical examination, complete blood count and chemical parameters, bone marrow biopsy, computed tomography and/or ultrasound.
Almost all patients (92%) were given chemotherapy as firstline therapy according to the CHOP regimen 18 (n ¼ 41) or the ProMACE-CytaBOM regimen 19 (n ¼ 22). One patient was initially treated with IMVP16, 20 and one with CEOP-IMVPDexa. 21 One patient died before treatment could be started. In all, 16 patients (24%) received additional radiotherapy.
The state of remission was evaluated after three or six cycles of chemotherapy depending on the initial stage. Patients with stage I disease, who had achieved complete remission after 3 cycles, were given three to four cycles of chemotherapy followed by local radiotherapy (n ¼ 4). Complete remission (CR) was defined as the disappearance of all clinical, radiographic and laboratory abnormalities after completion of therapy according to International Working Group recommendations. 22 Second-line therapy consisted of IMVP16 20 (n ¼ 7), DHAP 23 (n ¼ 6) or MiniBEAM 24 (n ¼ 8). Seven patients received more than two regimens.
Peripheral stem cell apheresis and subsequent peripheral blood stem cell transplantation (PSCT) were performed in 14 patients. The conditioning regimen consisted of fractionated total body irradiation in combination with high-dose cyclophosphamide, BEAM or CBV. 25 
Statistical analysis
Survival curves were calculated from the date of diagnosis until death or last follow-up in accordance with the Kaplan-Meier method. 26 Disease-free survival (DFS) was calculated from the date of CR until diagnosis of the first relapse. Statistical significance of observed differences was calculated with the Fisher's exact test and the log-rank test. 27 
Histology and immunohistochemistry
Histological examination was carried out on formalin-fixed (7.5%, pH 7.4), paraffin-embedded tissue. Sections were stained with hematoxylin and eosin, periodic acid Schiff and Giemsa for routine histopathological evaluation. The lymphomas were classified according to the Kiel, the REAL and the WHO classifications at the Institute of Clinical Pathology, Vienna General Hospital. Immunohistochemistry was performed on paraffin-embedded tissue sections as described. 28 Every case was required to be positive for CD20 or CD79a (B lineage) and negative for CD3 (T lineage) (antibodies were from Dako, Copenhagen, Denmark), thus confirming B-cell nature. During the review process, all cases were further investigated immunohistochemically. The panel of additional antibodies used was as follows: CD43 (Becton-Dickinson, San Jose, CA, USA); CD5, CD10, CD22, CD23 (all from Novocastra, Newcastle, UK); C3d (CD21), BCL2, BCL6, Vs38c, CD30, ALK-1, EMA, antibodies against both immunoglobulin heavy and light chains, LMP-1 (all from Dako), cyclin-D1 (Ylem, Rome, Italy); MIB-1 (Immunotech, Marseille, France), syndecan/CD138 (Serotec, Raleigh, USA) and MUM-1/ICSAT-1 (Santa Cruz, Santa Cruz, USA). The staining of tumor cells was scored as follows: negative (o5% of tumor cells reactive), weakly/moderately positive (5-50% stained tumor cells) and strongly positive (450% reactive tumor cells).
EBER in situ hybridization
For the detection of Epstein-Barr virus (EBV) early RNA transcripts (EBERs), fluorescein-labeled oligonucleotides complementary to EBER 1/2 were used according to the instructions of the manufacturer (PNA ISH detection kit, Dako) under RNAse-free conditions.
Fluorescence in situ hybridization (FISH) studies PB/PC-F and CB specimens used for interphase FISH analysis included either touch preparations of lymph nodes or paraffinembedded tissue. For the determination of copy numbers of chromosome 17 centromere and the TP53 gene at 17p13.1, DNA probes were obtained from Vysis (Downers Grove, IL, USA). Touch preparations were fixed with Carnoy's solution (methanol/glacial acetic acid 3:1 (vol/vol)) and then processed as detailed in a previous report. 29 Sections of paraffin-embedded lymphoid tissue (4 mm) were placed on coated microscope slides and dewaxed in xylene. Slides were then immersed in 100% ethanol two times for 5 min and air-dried. After fixation with 1% formaldehyde in phosphate-buffered saline (PBS) for 10 min and PBS washes, slides were incubated in sodium thiocyanate (Sigma, St Louis, MO, USA; 8.1 g in 100 ml distilled water) at 801C for 10 min, followed by three washes at room temperature and digestion in proteinase K solution (Boehringer, Mannheim, Germany; 10 mg in 1 ml Carlsberg solution) at 371C for 10 min. Slides were washed in PBS, dehydrated by processing through an ethanol series (70, 85, and 100% ethanol; 2 min each) and air-dried. DNA probes were added to the tissue sections and both were denatured together at 851C for 7 min in a HYBrite hybridization system (Vysis, Downers Grove, IL, USA) and hybridized at 371C overnight. After three washes in formamide (50% in 2 Â SSC) at 451C and two washes in 2 Â SSC at 371C, cells were counterstained with Vectashield mounting medium with DAPI (Vector Laboratories Inc., Burlingame, CA, USA).
To determine the cutoff level for the presence of a TP53 gene deletion, 10 reactive lymph-node specimens were analyzed, and evidence for one hybridization signal with the TP53-specific probe was obtained in 2.671.1% (mean7s.d.) of cells. This was not significantly different from the results observed in normal peripheral blood and bone marrow specimens (3.371.8%). The cutoff level would therefore be 8.5% (mean þ 3 s.d.). To further enhance the specificity, we only regarded one hybridization signal with the TP53 probe in 410% of cells as evidence for a deletion.
Molecular analysis of immunoglobulin V H genes
DNA from the diagnostic sample was amplified in two PCR rounds with a set of primers designed to detect the seven human V H families. PCR products were subcloned, sequenced and compared with the germline genes with the highest homology as described. 30 
Results
Histopathological criteria of DLBCL morphological variants
The histopathological criteria for assessing a diagnosis of CB, IB or PB/PC-F were mainly based on the morphological features of a given tumor entity listed in the updated Kiel classification. 7 The detailed histopathological criteria for the diagnosis of PB/ PC-F given in Table 1 were the result of a consensus meeting between two Viennese (ISK, AC) and a German hematopathologist (GO) in Vienna who reviewed and subclassified a total of 66 DLBCL on high-quality Giemsa-stained sections. In the first step, independent review of these cases without the knowledge of the other's interpretation, clinical course and immunophenotype yielded an interobserver agreement in 93.5% of cases.
All cases were then discussed on a multiheaded microscope and the three hematopathologists agreed on the histopathological criteria of CB, IB and PB/PC-F, as outlined in Table 1 . A consensus diagnosis was finally achieved for all 66 DLBCL entering this study (CB, n ¼ 44; IB, n ¼ 7; PB/PC-F, n ¼ 15). It was agreed upon that PB/PC-F is morphologically characterized by a spectrum probably reflecting maturation from an early to a late postgerminal center-cell transition as shown in Figure 1 . This spectrum ranges from a lymphoma rich in plasmablasts without mature plasma-cell-like elements (in Figure 1a) to a neoplasm composed of a mixture of plasmablasts, plasmacytoid cells and plasma cells (in Figure 1c) . Image B represents a morphologic intermediate between the two extremes showing plasmablastic and plasmacytoid cells.
Immunophenotypic characteristics of DLBCLmorphological variants
Immunohistochemically, tumor cells of 65/66 cases were positive for CD20 and CD79a; only one case lacked CD20 expression. No case showed the expression of CD23, CD5, CD43 or cyclin-D1. Tumor cells of all morphologic variants were negative for EBER and LMP-1, indicating no association with EBV.
Nine of the 15 cases of PB/PC-F were immunoreactive for the plasma-cell-associated antibody Vs38c, whereas only one case of CB showed faint reactivity. In IB lymphomas, Vs38c staining was absent. Two PB/PC-F showed very faint positivity with CD10, whereas 4/4 IB were CD10À. Only 3/16 CB cases tested were CD10 þ .
All PB/PC-Fs shared pronounced plasmacytoid differentiation ('secretoric activity') as visualized by large amounts of intracytoplasmic immunoglobulin heavy-chain gene products, which were IgM in 14 and IgG in the remaining case. In all 15 cases, intracytoplasmic k light chains could be demonstrated. In all, 16/21 CB cases and 2/5 IB cases did not show intracytoplasmic immunoglobulins; five CB and three IB showed rather faint staining with k (three CB, two IB) or l (two CB, one IB). All PB/PC-F showed the expression of bcl-2 in at least 50% of tumor cells. The strong expression of bcl-2 was found in 11/16 CB and all IB (4/4) tested. Of the 15 PB/PC-F, one showed strong cytoplasmic, vaguely granular staining of ALK-1 as well as EMA. FISH analysis in this case was performed with probes flanking the ALK gene; this probe design should allow the identification of any given in-frame ALK translocation by a clearcut split signal. In our case, however, no translocation could be detected, thus confirming the expression of full-length ALK transcripts (data not shown). Within the lymphomatous infiltrate of PB/PC-F, staining for CD21 and CD23 disclosed the complete absence of any follicular dendritic cell networks. The proliferation fraction, assessed by staining with the antibody MIB-1, was high (median, 70%; range, 60-90%).
Expression of bcl-6, syndecan/CD138 and MUM-1/ICSAT-1
In addition, the expression of bcl-6, syndecan/CD138 and MUM-1/ICSAT-1 in the three different morphological variants of DLBCL was investigated (Table 2, Figure 2) .
Of the 14 PB/PC-F cases investigated, 13 (93%) showed the expression of MUM-1/ICSAT-1, whereas the expression of this antigen was less pronounced in CB and IB (72 and 75%, respectively). In contrast, bcl-6 expression was more prominent in CB (82%) and IB (50%), whereas the vast majority of PB/PC-F was bcl-6 negative (67%). Of the 15 PB/PC-F cases, three (20%) clearly expressed syndecan/CD138, whereas none of the CB or IB samples showed reactivity for this antibody.
FISH analysis
Interphase FISH was used to determine TP53 gene copy numbers in PB/PC-F specimens from 13 patients. In 11 of these patients (84.6%), a monoallelic deletion of the TP53 gene was observed, occurring in 21.0-93.6% of cells (median, 48.0%) (Figure 3) . Two patients had a concomitant loss of both the chromosome 17 centromeric region and the TP53 gene Impact of plasmablastic features on DLBCL outcome I Simonitsch-Klupp et al indicating monosomy 17, whereas in the remaining nine patients, a disomic or trisomic pattern of the chromosome 17 centromeric region was obtained, suggesting a partial loss of 17p including the TP53 gene locus. In contrast, FISH results with the TP53-specific probe were normal in all seven cases of CB lymphomas and three cases of IB lymphomas studied.
Molecular analysis of IgH V H genes
V H gene usage and mutation pattern were analyzed in 10/15 PB/ PC-F specimens. In agreement with previously published data on DLBCL, 32 ,33 a preferential use of V H4 (four VH 4-34 , two VH 4-04 ) was found. Two patients had a V H3 and two patients a V H1 idiotype. The average mutation rate was 5.39%. Two patients had less than 2%, and six patients 45% mutations compared to the best-matched V H germline sequence. These findings indicate that the majority of these lymphomas are of germinal center or postgerminal center origin.
Pretreatment characteristics
The clinical and laboratory characteristics of all patients grouped by histological classification are listed in Tables 3  and 4 . Of the 66 patients, 44 (67%) had CB, seven (10%) IB and 15 (23%) had PB/PC-F. In all, 60% of patients with PB/PC-F were over 60 years of age, 53% had an elevated LDH. A total of 53% had stage III/IV disease, but none of these parameters reached statistical significance. Patients with IB and PB/PC-F had more frequently B symptoms than CB-DLBCL (Po0.05). Patients with PB/PC-F had a tendency for more extranodal manifestations and a higher IPI risk score (8/15 patients with three to five RFs), but these differences were not statistically significant. There were no major differences regarding gender or b 2 -microglobulin serum levels between CB, IB and PB/PC-F.
Three of the 15 patients with PB/PC-F had a serum paraprotein (two IgM, one IgG, corresponding to the immunoglobulin expressed in the tumor cells). Seven of the 15 patients were HIV negative, while no tests were available for the others. However, there was no clinical evidence for the risk of HIV infection or AIDS in these remaining patients. Interphase FISH analysis with a TP53-specific probe (red signals), hybridized simultaneously with a chromosome 17-specific centromeric probe (green signals). The majority of cells are characterized by a deletion of TP53.
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Response to treatment
The overall complete response rate was 65% (43/66) for the whole group (Table 5 ). The analysis of the three subgroups exhibited a lower CR rate (47%), for PB/PC-F vs CB lymphoma patients, although statistically not significant. In addition, PB/ PC-F patients had a high early death rate as well as a 71% relapse rate after standard chemotherapy (5/7 patients). Moreover, the three patients who received an autologous peripheral blood stem cell transplant relapsed within 6 months and died from progressive disease, while seven out of 10 patients with CB lymphoma are still alive in CR after PSCT.
Survival
The estimated OS for the whole group was 47% at 60 months with a median observation time of 51 months. As shown in Figure 4 , there is a major difference in survival between the PB/ PC-F patients and the other subgroups. Patients with CB or IB lymphoma had an estimated 5 years OS of 56 or 57%, respectively. In contrast, patients with PB/PC-F had a median OS of only 14 months (Po0.002).
The estimated DFS was 48% at 60 months. Patients with CB or IB lymphoma had a DFS of 50 or 75%, respectively, at 5 years (not shown). The median DFS for patients with PB/PC-F was 6 months (P ¼ 0.02), with only two patients remaining in first CR after 15 months. Within the low and low-intermediate IPI groups (0-2 RFs), PB/PC-F patients had a significantly shorter OS (median OS for PB/PC-F: 14.7 months, but still not reached in the CB plus IB group; Po0.001; Figure 5 ). This indicates that the morphological variant maintains its independent prognostic value within the low and low-intermediate IPI subgroup. Interestingly, the difference between the PB/PC-F and CB plus IB groups was no longer significant in patients with three to five IPI due to the poor survival of patients with CB/IB lymphomas (median OS 9 vs 14 months; P ¼ 0.12; not shown).
Discussion
DLBCL represent a group of aggressive lymphoid tumors composed of six morphological variants in the WHO classification. 3 The variants listed in the WHO classification are cytologically diverse, but it has been noted that distinction between these Impact of plasmablastic features on DLBCL outcome I Simonitsch-Klupp et al variants has met with poor intra-and interobserver reproducibility, 3 and therefore it remains optional for the pathologist to use only the common term of DLBCL or to specify a specific morphological variant. Also, most immunophenotypic and genotypic investigations have not aided in the delineation of the various subtypes, and therefore the WHO committee proposed to find new criteria.
Over the past decade, we have observed single cases of DLBCL that did not exactly meet the morphologic criteria of CB or IB morphology, but instead shared plasmablastic/plasmacytoid morphology. Therefore, we tried to specify this subgroup of lymphomas and to look for specific features. A number of characteristics emerged from this study. These included not only morphological features but also phenotypic and genotypic peculiarities, which may explain the resistance of these lymphomas to conventional therapy as well as their detrimental clinical outcome.
Morphologic, immunophenotypic and genotypic features of PB/PC-F
Based on the proposed morphological features of the three subtypes of DLBCL investigated, we were able to achieve concordance in the vast majority of cases. Surprisingly, the diagnostic controversy in six cases comprised only the discrimination between CB vs PB/PC-F, but not between IB vs PB/PC-F, as expected previously. According to the applied criteria, 15/66 lymphomas (23%) were classified as PB/PC-F. It is worth noting that cases of IB with plasmacytic differentiation as described in the Kiel classification 7 are incorporated into the group of lymphomas with PB/PC-F. This fact may explain the relatively high number of these cases in our series (23%).
The immunophenotype of PB/PC-F described herein is predominantly IgM þ , CD20 þ , with the expression of Vs38c in more than 50% of the cases and a lack of EBV association. Further characterization with antibodies against antigens related to B-cell development disclosed strong expression of MUM-1/ ICSAT-1 in 13/14 cases, whereas the vast majority was negative for bcl-6. Three of 15 cases showed additional expression of syndecan/CD138. The latter cases did not show any bcl-6 expression, but were strongly reactive with MUM-1/ICSAT-1. This peculiar phenotype corresponds to the very late or activated stage in B-cell maturation already described. 31 It has also been noted previously that lack of bcl-6 mRNA and protein expression in DLBCL is associated with short OS and DFS. 32 In all, 12 patients were negative with syndecan/CD138, showed variable expression of bcl-6 and were uniformly MUM-1/ICSAT-1 þ , most likely corresponding to the category of late germinal/ early postgerminal center B cells. Finally, one case showed a germinal center B-cell phenotype with the expression of bcl-6, but lack of syndecan/CD138 and MUM-1 expression.
The fact that only one case of our series was CD20À was a rather surprising finding, since most plasmablastic lymphomas already listed in the WHO classification are CD20À and are composed of tumor cells related to plasma-cell stage. It is likely that most of our CD20 þ lymphomas belong to the early postgerminal stage of differentiation, and thus are not entirely Table 5 Response to therapy and survival Lymphoma subtype CB, n (%) IB, n (%) PB/PC-F, n (%) 
PB/PC-F are associated with poor clinical outcome and resistance to chemotherapy
Patients with PB/PC-F had a tendency towards extranodal manifestations and B symptoms. On the other hand, there was no significant difference in LDH or stage compared to CB or IB lymphomas. Our patients had a slightly higher IPI, but this difference was not significant. However, almost half of the patients had only 0-2 RFs and still achieved no remission or relapsed. The initial response to doxorubicin-based regimens was poor, and five of the seven patients who achieved a CR relapsed within 9 months. Moreover, the three patients who underwent PSCT also relapsed, indicating total resistance to conventional treatment resulting in a median OS of only 14 months.
Strikingly, there was a high incidence of TP53 deletions detected by FISH in our patients. This feature was associated with poor prognosis in other series. 35 On the other hand, there is currently no information on specific cytogenetic abnormalities in PB/PC-F. 36 In anthracyclin-resistant disease, multidrug resistance genes might also play a role. 37 Of note, 'activated B-like' DLBCLs defined by microarray screening also have a poor prognosis. 10, 11 Since PB/PC-F relapses early and seems to be refractory to PSCT, these patients might be candidates for alternative treatment strategies like allogeneic bone marrow transplantation or additional B-cell antibody therapy. 38 
Spectrum of plasmablastic lymphomas in the WHO classification
Plasmablastic morphology may be found in a spectrum of different lymphoma variants now listed separately in the WHO. It has been described in HIV-positive patients with lymphomas of the oral cavity. 13 This group has an immunophenotype closely resembling the plasma-cell stage of differentiation (IgG þ , CD20À,Vs38c þ ). The lymphomas may be differentiated from multiple myeloma with plasmablastic features by the absence of a monoclonal serum protein. 39 Interestingly, paraproteinemia of IgM or IgG type was found in three of our PB/PC-F patients without evidence for a preceding or concomitant indolent lymphoma or multiple myeloma.
A separate variant is acknowledged in the WHO classification, which is termed 'DLBCL with full-length ALK expression'; of note, most tumors of this variant are also composed of cells with plasmablastic differentiation, and one of our cases meets the criteria of this variant listed. Recently, it has been shown that ALK activation in many of these B-cell lymphomas is due to a chromosomal translocation involving the CLTC gene on chromosome 17 instead of the overexpression of full-length ALK. 15, 16 Even the 'classical' t(2;5)(p23;q35) with NPM as the fusion partner driving ALK overexpression has been reported to occur in DLBCL with plasmablastic morphology. 17 However, our lymphoma case lacks evidence of an altered ALK gene configuration, and it remains to be determined if the presence of ALK is a mere accident rather than an oncogenic phenomenon in these translocation-negative cases, in a similar manner as has been demonstrated for neuroblastomas expressing full-length ALK. 40 HHV-8-associated plasmablastic lymphomas have also been described recently.
14 Taken together, the term 'plasmablastic' is applied for a wide variety of lymphomas with different biologic, phenotypic, genotypic and morphologic features. We are aware that in daily practice, the histologic features alone may serve as guidelines, OS of patients with low and low-intermediate risk (IPI 0-2). PB/PC-F maintains its prognostic significance (Po0.001).
Impact of plasmablastic features on DLBCL outcome I Simonitsch-Klupp et al but for themselves are insufficient for diagnostic use. Consequently, a raised level of suspicion should lead to additional laboratory investigations. With regard to common clinical features, one could argue that all the subgroups reported should be included into a category of 'plasmablastic lymphoma' as part of DLBCL. It should be stated, however, whether a given lymphoma is immunodeficiency associated.
In conclusion, we propose morphologic criteria for the distinction of PB/PC-F from other morphologic variants of DLBCL. We are aware that morphological features of a given variant of DLBCL are difficult to reproduce; the detailed morphological criteria for the diagnosis of PB/PC-F provided herein were the result of a consensus meeting between two centers and by applying these criteria, interobserver agreement was achieved in 93.5% of cases. In our series, the patients had a poor clinical outcome. We feel that these data warrant application of our diagnostic criteria as well as evaluation of their prognostic impact by other institutions.
